Author
Listed:
- Yuna Blum
(Ligue Nationale Contre Le Cancer)
- Clément Meiller
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Lisa Quetel
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Nabila Elarouci
(Ligue Nationale Contre Le Cancer)
- Mira Ayadi
(Ligue Nationale Contre Le Cancer)
- Danisa Tashtanbaeva
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Lucile Armenoult
(Ligue Nationale Contre Le Cancer)
- François Montagne
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology
Hôpital Calmette - CHRU de Lille
Université de Lille)
- Robin Tranchant
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology
PSL Research University, CNRS UMR8231 Chimie Biologie Innovation)
- Annie Renier
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Leanne Koning
(PSL Research University)
- Marie-Christine Copin
(Université de Lille
Institut de Pathologie, Centre de Biologie-Pathologie, CHRU de Lille)
- Paul Hofman
(Laboratoire de Pathologie Clinique et Expérimentale (LPCE) et biobanque (BB-0033-00025), CHRU de Nice
Université Côte d’Azur)
- Véronique Hofman
(Laboratoire de Pathologie Clinique et Expérimentale (LPCE) et biobanque (BB-0033-00025), CHRU de Nice
Université Côte d’Azur)
- Henri Porte
(Hôpital Calmette - CHRU de Lille
Université de Lille)
- Françoise Pimpec-Barthes
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology
Hôpital Européen Georges Pompidou
Hôpital Européen Georges Pompidou)
- Jessica Zucman-Rossi
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Marie-Claude Jaurand
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
- Aurélien Reyniès
(Ligue Nationale Contre Le Cancer)
- Didier Jean
(Sorbonne Universités, Inserm, UMRS-1138
Université Paris Diderot, Université Paris 13, Labex Immuno-Oncology)
Abstract
Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Molecular profiling studies have not addressed intra-tumor heterogeneity in MPM to date. Here, we use a deconvolution approach and show that molecular gradients shed new light on the intra-tumor heterogeneity of MPM, leading to a reconsideration of MPM molecular classifications. We show that each tumor can be decomposed as a combination of epithelioid-like and sarcomatoid-like components whose proportions are highly associated with the prognosis. Moreover, we show that this more subtle way of characterizing MPM heterogeneity provides a better understanding of the underlying oncogenic pathways and the related epigenetic regulation and immune and stromal contexts. We discuss the implications of these findings for guiding therapeutic strategies, particularly immunotherapies and targeted therapies.
Suggested Citation
Yuna Blum & Clément Meiller & Lisa Quetel & Nabila Elarouci & Mira Ayadi & Danisa Tashtanbaeva & Lucile Armenoult & François Montagne & Robin Tranchant & Annie Renier & Leanne Koning & Marie-Christine, 2019.
"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications,"
Nature Communications, Nature, vol. 10(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09307-6
DOI: 10.1038/s41467-019-09307-6
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09307-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.